ニュース

If you are wondering whether Johnson & Johnson at around US$226.71 is still a strong long term holding or starting to look stretched, the answer starts with understanding what you are really paying for today. The stock is up 2.4% over the past week, down 3.2% over the past month, and sits on a 9.3% year to date return, with a 54.0% one year return, 56.0% over three years, and 52.7% over five years. This gives you a wide range of recent price behaviour to put under the microscope. Recent...

HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.

BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.

Markets are on the rise, but worries about a recession remain elevated as May gets underway.

These companies pay some of the world's most bankable dividends.

They have combined for 118 years of consecutive dividend increases.

It's hard to argue against its reliability.